These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32742988)

  • 21. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
    Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and resource utilization of
    Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
    Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel.
    Paredes de la Fuente R; Sucre S; Ponce C; Rattani AAA; Peters MLB
    Cancers (Basel); 2024 Aug; 16(15):. PubMed ID: 39123462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
    Servetto A; Santaniello A; Napolitano F; Foschini F; Marciano R; Mozzillo E; Cascetta P; Amato AR; Augurio MR; Maresca L; De Placido P; De Placido S; Formisano L; Bianco R
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of advanced pancreatic leiomyosarcoma treated with gemcitabine plus
    Kikuchi Y; Nishikawa Y; Amanuma M; Kishimoto Y; Takuma K; Wakayama M; Shibuya K; Okano N; Shimada H; Igarashi Y
    Int Cancer Conf J; 2021 Jan; 10(1):63-67. PubMed ID: 33489704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer.
    Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
    World J Clin Cases; 2020 Sep; 8(17):3718-3729. PubMed ID: 32953848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis.
    Parmar A; Chaves-Porras J; Saluja R; Perry K; Rahmadian AP; Santos SD; Ko YJ; Berry S; Doherty M; Chan KKW
    Crit Rev Oncol Hematol; 2020 Jan; 145():102817. PubMed ID: 31955005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
    Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
    Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients.
    Ning Z; Xie J; Chen Q; Zhang C; Xu L; Song L; Meng Z
    Onco Targets Ther; 2019; 12():1021-1029. PubMed ID: 30774386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
    Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
    Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer.
    Shi Z; Yang J; Kong W; Qiu X; Lu C; Liu J; Liu B; Du J
    Front Oncol; 2022; 12():782730. PubMed ID: 35299738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.
    Van Cutsem E; Collignon J; Eefsen RL; Ochsenreither S; Zvirbule Z; Ivanauskas A; Arnold D; Baltruskeviciene E; Pfeiffer P; Yachnin J; Magnusson S; Rydberg Millrud C; Sanfridson A; Losic N; Garcia-Ribas I; Tersago D; Awada A
    Clin Cancer Res; 2024 Dec; 30(23):5293-5303. PubMed ID: 39385434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer.
    Lim JY; Cho JH; Lee SJ; Lee DK; Yoon DS; Cho JY
    Cancer Res Treat; 2015 Apr; 47(2):266-73. PubMed ID: 25327494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC).
    Olowokure O; Torregroza-Sanchez MP; Bedoya-Apraez ID
    J Gastrointest Oncol; 2013 Jun; 4(2):E16-8. PubMed ID: 23730523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report.
    Comito F; Grassi E; Poerio A; Freier E; Calculli L; Zompatori M; Ricci C; Casadei R; Di Marco M
    BJR Case Rep; 2018; 4(2):20170086. PubMed ID: 30363157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.
    Pijnappel EN; Wassenaar NPM; Gurney-Champion OJ; Klaassen R; van der Lee K; Pleunis-van Empel MCH; Richel DJ; Legdeur MC; Nederveen AJ; van Laarhoven HWM; Wilmink JW
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy
    Han SY; Kim DU; Seol YM; Kim S; Lee NK; Hong SB; Seo HI
    World J Clin Cases; 2020 Sep; 8(18):4022-4033. PubMed ID: 33024759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.